1naresh2naresh<pre>Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

    [5860c239-08ae-4aa9-a2a9-a0038391b774] => Array
        (
            [runtime-id] => 5860c239-08ae-4aa9-a2a9-a0038391b774
            [type] => toll-free-key
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [bb0a0aa1-779d-4175-b669-1c91821d2ba8] => Array
                        (
                            [runtime-id] => bb0a0aa1-779d-4175-b669-1c91821d2ba8
                            [type] => toll-free-key
                        )

                )

            [credentials] => Array
                (
                    [method] => toll-free-key
                    [value] => tf_ipsecsha;7116d2ea6abd68573d8cd1f72be80df021007519
                )

        )

)
1naresh2naresh<pre>Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => FreeToRead
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

    [20eaaaf8-860e-4e9b-9fed-a0b7d5e50bfe] => Array
        (
            [runtime-id] => 20eaaaf8-860e-4e9b-9fed-a0b7d5e50bfe
            [type] => toll-free-key
            [service-id] => ajnr-ac.highwire.org
            [access-type] => FreeToRead
            [privilege] => Array
                (
                    [c11df889-3b36-411e-b4c6-df03169a0d9c] => Array
                        (
                            [runtime-id] => c11df889-3b36-411e-b4c6-df03169a0d9c
                            [type] => toll-free-key
                        )

                )

            [credentials] => Array
                (
                    [method] => toll-free-key
                    [value] => tf_ipsecsha;7116d2ea6abd68573d8cd1f72be80df021007519
                )

        )

)
RT Journal Article
SR Electronic
T1 Rituximab (Rituxan)
JF American Journal of Neuroradiology
JO Am. J. Neuroradiol.
FD American Society of Neuroradiology
SP 1178
OP 1180
DO 10.3174/ajnr.A2142
VO 31
IS 7
A1 Selewski, D.T.
A1 Shah, G.V.
A1 Mody, R.J.
A1 Rajdev, P.A.
A1 Mukherji, S.K.
YR 2010
UL http://www.ajnr.org/content/31/7/1178.abstract
AB SUMMARY: Rituximab is a monoclonal antibody that was first approved by the FDA as an antineoplastic agent designed to treat B-cell malignancies. This article will review the mechanism of action and clinical role of this anti-B-cell agent. FDAUS Food and Drug AdministrationFSEfast spin-echo